[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromuscular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromuscular-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,55,87,130,190,230,263,292,315,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100598472","phase-2-a-clinical-trial-of-early-ventilation-in-amyotrophic-lateral-sclerosis-event-als-100598472",false,"NCT07071935","A Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","EVENT ALS","Inclusion Criteria:\n\n* Diagnosed with ALS using the Gold Coast Criteria within the last 6 months\n* Age ≥18 years\n* Willingness and ability to participate in study procedures\n* Provision of signed and dated informed consent form\n\nExclusion Criteria:\n\n1. Current or prior or recommended\u002Fprescribed use of NIV including:\n\n   i) bi-level positive pressure ventilation, such as a respiratory assist device or home ventilator ii) Current or prior use of continuous positive airway pressure, or \"CPAP\" therapy\n2. Forced vital capacity \\\u003C50% of predicted normal\n3. Maximal inspiratory pressure \\> -60 cmH2O (eg, -50 or -40 cmH2O would be excluded)\n4. Chronic use of supplemental oxygen at any part of the day\n5. Enrollment in hospice\n6. Current tracheostomy\n7. Prior history of sleep apnea where non-invasive ventilation was used or recommended\n8. Thoracic, abdominal, facial or ophthalmic surgery in the prior 6 weeks\n9. Coughing up blood\n10. Myocardial infarction in the previous 4 weeks\n11. Absolute contraindication to NIV, which includes lethargy, obtundation, facial fractures, active pneumothorax, and airway obstruction (such as a tumor)\n12. Presence of cognitive dysfunction that would impair ability to complete study procedures, as determined by neurology attending physician","ALL","18 Years",{"count":20,"type":21},48,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. The investigators do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, there is no evidence-based guidance on the best way to adjust NIV to benefit patients as much as possible. Some patients have difficulty tolerating NIV, but it is not clear how to identify these individuals ahead of time.\n\nThe investigators have created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help the study team identify who is more likely to benefit from starting NIV early. The investigators have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit with use NIV for at least 4 hours per day. The investigators published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer when CO2 levels are lowered using NIV. The investigators also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.\n\nIn this study, the investigators will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. The research team will first use their previously published prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as would occur if the participants were not in the study.\n\nThe purpose of this study is to collect data to help the investigators plan a larger randomized clinical trial. This study has 4 objectives. First, the project aims to identify individuals who would benefit from earlier NIV. The research team will use the original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, the project aims to show that it is feasible to start NIV early. Third, the project aims to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, the project aims to identify traits that may make someone less likely to use NIV.",[27,28,29,30,31,32,33,34,35,36],"Amyotrophic Lateral Sclerosis (ALS)","Chronic Respiratory Failure","Neuromuscular Disease Patients","Neuromuscular Disease","Respiratory Insufficiency","Respiratory Insufficiency Requiring Mechanical Ventilation","Positive Pressure Ventilation","Non-invasive Ventilation","Non-invasive Ventilation Support","Non-invasive Ventilatory Support",[38,39,40,41],"chronic respiratory failure","chronic neuromuscular respiratory failure","non-invasive ventilation","amyotrophic lateral sclerosis","RECRUITING","2026-06-25",{"date":45,"type":46},"2026-06-26","ACTUAL",{"date":48,"type":46},"2026-06-11",{"date":50,"type":21},"2029-05",{"name":52,"class":53},"University of Pennsylvania","OTHER",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100201553","electrical-impedance-myography-natural-history-studies-inneuromuscular-disorders-and-healthy-volunteers-100201553","NCT01900132","Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers","Electrical Impedance Myography: Natural History Studies in Neuromuscular Disorders and Healthy Volunteers","* INCLUSION CRITERIA:\n\nHEALTHY VOLUNTEERS-ADULTS\n\n1. Healthy adults, male or female, aged 18 years old or older,\n2. In good general health as evidenced by medical history\n3. Stated willingness to comply with all study procedures and availability for the duration of the study.\n4. Ability of subject to understand and the willingness to sign a written informed consent document.\n\nHEALTHY VOLUNTEERS-PEDIATRIC\n\n1. Healthy children, male or female, age 7-18,\n2. In good general health as evidenced by medical history\n3. Stated willingness to comply with all study procedures and availability for the duration of the study\n4. Ability of subject or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document.\n\nSUBJECTS WITH NEUROMUSCULAR DISEASE\n\nAdult and pediatric, male or female, patients with a neuromuscular disorder are eligible even if the exact etiology of the disorder is unknown at the time of enrollment into this study. This will include neuropathy, myopathy and motor neuron disorders. It is expected that the subjects are undergoing appropriate standard diagnostic and genetic work-up outside of this protocol that will later clarify the specific etiology of the disorder. Movement disorder will also be included because of the prior research done on dystonia and EIM.\n\nInclusion criteria\n\n1. Suspected motor neuron disease or\n2. Suspected myopathy or\n3. Suspected neuropathy or\n4. Suspected movement disorders that impair intracortical processes\n5. Age of 2 years or older\n6. Ability of subject to sign a written informed consent document.\n\nNIH EMPLOYEES:\n\nNIH employees and staff may participate, however EMG Section, OCD, NINDS, employees may not participate.\n\nEXCLUSION CRITERIA:\n\nHEALTHY VOLUNTEERS-ADULTS\n\n1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease.\n2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery\n\nHEALTHY VOLUNTEERS-PEDIATRIC\n\n1. Medical conditions that require medications that affects the physiological measures being tested. Some conditions that may be excluded are diabetes, kidney and liver disease.\n2. History of stroke, muscle disorders, peripheral neuropathy or spine surgery\n\nSUBJECTS WITH NEUROMUSCULAR DISEASE:\n\nNo clinical evidence of a neuromuscular disorder on clinical evaluation.",true,"2 Years","110 Years",{"count":66,"type":21},275,[68],"NA","Background:\n\n\\- Electrical impedance myography (EIM) is a new technique being studied to see if it is helpful in evaluating muscle disorders and nerve disorders. EIM looks at how a mild, painless electrical current travels through muscles. Researchers want to gain experience in using the EIM device. They will collect information on the results of using it on people with and without nerve and muscle diseases, and compare that with information from other standard tests. First, they will test the device on healthy people. Then they will test people with a variety of neuromuscular diseases. Because the test is noninvasive and not painful, researchers will test both children and adults.\n\nObjectives:\n\n\\- To gain experience using the EIM muscle testing device.\n\nEligibility:\n\n* Healthy volunteers at least 2 years old.\n* Individuals at least 2 years old who have neuromuscular disease.\n\nDesign:\n\n* Participants will be screened with a medical history and physical exam.\n* Participants will have one 2-3 hour clinic visit. Researchers may request follow-up visits.\n* Participants will be tested with the EIM device. The device and small electrodes will be placed on their skin. An electric current will pass through the device, but the participants will not feel this.\n* Participants may have an ultrasound test. A gel will be put on their skin, and a device will be moved over the skin.\n* Participants may have a nerve test. Electrodes will be placed on their skin, and they will feel a small shock.\n* Participants may have a test where a thin needle is inserted in their muscle.",[30,71,72,73],"Motor Neuron Disease","Inherited Neuromuscular Conditions","Inherited Neuropathies",[75,30],"Electrophysiology","2026-06-23",{"date":78,"type":46},"2026-06-24",{"date":80,"type":46},"2013-06-20",{"date":82,"type":21},"2027-06-01",{"name":84,"class":85},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":99,"conditions":100,"keywords":113,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":86},"100600783","hyperthermia-in-patients-with-chronic-primary-pain---effects-on-thermoregulation-somatosensory-system-and-movement-evoked-pain-100600783","NCT07101978","Hyperthermia in Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System and Movement Evoked Pain","Hyperthermia in Healthy and Patients With Chronic Primary Pain - Effects on Thermoregulation, Somatosensory System, Movement Evoked Pain (HYPPRI-1)","HYPPRI-1","Inclusion Criteria:\n\npatients:\n\n* Confirmed diagnosis of widespread pain (ICD-11 MG30.01)\n* Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) scale ≥ 5 or WPI) ≥ 3 and SS ≥ 9,\n* Pain \\>= 3 month and VAS \\>= 4,0\n* Body - infrared-A-Bulb Distance \\\u003C 38cm (overweight participants)\n* Signed declaration of consent\n\nhealthy:\n\n* No chronic illnesses\n* No acute infections\n* No regular medication: To avoid interactions\n* BMI ≤ 40kg\u002Fcm2\n* Mental health: No psychiatric diagnoses or psychotropic medication in your medical history\n\nExclusion Criteria:\n\n* Participation in other clinical studies\n* Contraindications for hyperthermia (severe cardiovascular diseases, tumour diseases, acute infections, pregnant and breastfeeding women)\n* Acute and \u002F or feverish microbial infections\n* Participants with severe somatic, rheumatic concomitant endocrine or neurological diseases, in particular neurological diseases associated with cognitive disorders, severe liver or kidney and cardiac diseases\n* participants who are permanently treated with opioids, cannabis, immunosuppressive drugs (e.g. corticoids, immunosuppressants) or alpha\u002Fbeta-A(nta)gonists due to a disease from the group described above\n* participants with pain due to a serious psychiatric illness (bipolar disorder, psychosis, personality disorder, severe depression, substance abuse) and serious systemic or neurological disorders\n* pregnancy or breastfeeding (for women)\n* Intake of medication within 6 weeks that inhibits the reuptake of the neurotransmitter serotonin or binds to receptors of this neurotransmitter group","70 Years",{"count":97,"type":21},60,[68],"This study, in a quasi-experimental matched two-group pre-post design, investigates the effect of serial water-filtered whole-body hyperthermia on circadian core body temperature, the somatosensory system (nociception) and the movement evoked pain in healthy and patients with chronic primary pain (e.g., fibromyalgia). The intervention lasts 3 weeks with two treatment sessions per week.",[101,102,103,104,105,106,30,107,108,109,110,111,112],"Hyperthermia","Chronic Primary Pain","Widespread Pain","Muscular Disease","Rheumatic Diseases","Musculoskeletal Diseases","Fibromyalgia","Circadian Rhythm","Body Temperature Changes","Somatosensory Function","Quantitative Sensory Testing","Healthy",[114,115,116,117,118,119],"hyperthermia","widespread pain","chronic primary pain","circadian body temperature","quantitative sensory testing","healthy","NOT_YET_RECRUITING","2026-05-29",{"date":123,"type":46},"2026-06-02",{"date":125,"type":21},"2026-08-01",{"date":127,"type":21},"2028-12-31",{"name":129,"class":53},"Bern University of Applied Sciences",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":141,"conditions":142,"keywords":162,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":189},"100567749","phase-3-a-phase-3-study-of-ntla-2001-in-attrv-pn-100567749","NCT06672237","A Phase 3 Study of NTLA-2001 in ATTRv-PN","MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)","Inclusion Criteria:\n\n* Diagnosis of ATTRv-PN\n* Karnofsky Performance Status (KPS) ≥ 60\n\nExclusion Criteria:\n\n* Other causes of amyloidosis (amyloidosis caused by non-TTR protein)\n* Other known causes of sensorimotor or autonomic neuropathy\n* Diabetes mellitus\n* New York Heart Association Class III or IV heart failure\n* Liver failure\n* Hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Prior receipt of a TTR silencer (Small interfering RNA (siRNA) or Antisense oligonucleotides (ASOs))\n* Estimated Glomerular Filtration Rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n* Unable or unwilling to take vitamin A supplementation for the duration of the study\n* History of liver disease","85 Years",{"count":97,"type":21},[140],"PHASE3","This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.",[30,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161],"Neuromuscular Diseases (NMD)","Neurodegenerative Disease","Neurodegenerative Disease, Hereditary","Neurodegenerative Diseases","Neuromuscular Diseases","Nerve Disorders","Nervous System Disease","Nervous System Diseases","Genetic Disease, Inborn","Amyloidosis, Familial","Amyloidosis, Hereditary","Amyloidosis","Polyneuropathies","Amyloid Neuropathies","Amyloid Neuropathies, Familial","Peripheral Nervous System Disease","Peripheral Nervous System Diseases","Metabolism, Inborn Errors","Metabolic Diseases",[163,154,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178],"TTR","Polyneuropathy","NTLA-2001","ATTR","ATTR-PN","ATTRv-PN","Transthyretin","TTR-mediated amyloidosis","Amyloidosis, hereditary","Amyloidosis, hereditary, transthyretin-related amyloidosis","Transthretin amyloid polyneuropathy","TTR PN","TTR polyneuropathy","nexiguran ziclumeran","nex-z","CRISPR","2026-04-13",{"date":181,"type":46},"2026-04-16",{"date":183,"type":46},"2024-11-22",{"date":185,"type":21},"2028-08",{"name":187,"class":188},"Intellia Therapeutics","INDUSTRY",14,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":210,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":54},"100620423","connect-one-early-feasibility-study-of-connexus-brain-computer-interface-bci-100620423","NCT07357428","Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)","Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI) to Provide Human Connection Through Communication","CONNECT-ONE","Inclusion Criteria:\n\n* Clinical diagnosis of a progressive neuromuscular disease or a neurological injury.\n* Clinical diagnosis of anarthria or severe dysarthria.\n* Wheelchair dependent with severely impaired upper limb function.\n* Has a reliable method of communication and the ability to read and understand the English language.\n* Has a study care partner (e.g. caregiver or multiple caregivers) for the duration of the study.\n* Lives within a 4-hour radius of a study site.\n\nExclusion Criteria:\n\n* Cognitive impairment or psychiatric illness that could impact the ability to comply with study requirements, as determined by the Study Investigator.\n* Co-morbidities or an ongoing chronic medical condition that would impair the ability to comply with study requirements.\n* The presence of another implanted device, like a pacemaker, deep brain stimulator, or implantable pulse generator.\n* Requires, or is expected to require regular MRI scans for on-going medical conditions.\n* In the opinion of the Study Investigator, the patient is not an appropriate candidate for the study, for reasons that could place the patient at undue risk or otherwise result in non-compliance with the study requirements.","22 Years","75 Years",{"count":201,"type":21},2,[68],"The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with impaired communication as a result of severe loss of voluntary motor control; and (2) to provide control of computer devices for individuals with severe loss of voluntary motor control of the upper extremity.",[205,30,206,207,208,209],"Amyotrophic Lateral Sclerosis","Stroke","Tetraplegia\u002FTetraparesis","Cervical Spinal Cord Injury","Dysarthria",[211,212,213,214,215,216,217,218,219,220,221],"BCI","ALS","Paradromics","speech","dysarthria","neural injury","progressive neuromuscular disease","stroke","assistive technology","communication device","brain computer interface","2026-04-09",{"date":224,"type":46},"2026-04-14",{"date":226,"type":46},"2026-03-31",{"date":228,"type":21},"2032-01",{"name":213,"class":188},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":17,"minAge":237,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":241,"conditions":242,"keywords":248,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":86},"100602251","the-effects-of-a-dynamic-arm-support-in-daily-life-100602251","NCT07121075","The Effects of a Dynamic Arm Support in Daily Life","The Effects of a Dynamic Arm Support in Daily Life. A Mixed Methods Study Including the Different Components of the ICF","Inclusion Criteria:\n\n* Age: 16 and oler\n* Being able to understand and comprehend test instructions\n* Using a DAS from Focal Meditech (Balancer, Flowing, Dowing, Gowing 2 or Top Help)\n\nExclusion Criteria:\n\n\u002F","16 Years",{"count":239,"type":21},50,"OBSERVATIONAL","The goal of this mixed method study is to learn about how a dynamic arm support device (DAS) helps people with everyday activities. The study focuses on people with neuro(-muscular) conditions, age 16 and older. The research questions that are formulated, are:\n\n* How does a person experience their daily activities, with and without a DAS?\n* What are the contextual (external and personal) factors that influence the use of a DAS?\n\nParticipants will take part in three testing sessions. In each session, they must complete a few questionnaires and participate in an interview. The first time, without DAS. In the second and third session, they will be using their DAS (resp. 3 to 4 weeks and 3 months). The data collection will be executed by phone, digital questionnaires and\u002For paper.",[30,243,244,245,246,247],"Neuromuscular Disability","Assistive Technology","Activities of Daily Living","Occupational Therapy","Upper Limb",[249,250,251,252,253],"dynamic arm support","dynamic arm support device","ICF","daily life","outcome measures","2025-08-12",{"date":256,"type":46},"2025-08-13",{"date":258,"type":46},"2024-12-02",{"date":260,"type":21},"2026-08",{"name":262,"class":53},"Hasselt University",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":86},"100582124","new-technological-pathway-for-gait-rehabilitation-100582124","NCT06859229","New Technological Pathway for Gait Rehabilitation","Effects on Gait Patterns of a New Technological Pathway for Gait Rehabilitation in Patients With Movement Disorders","LABODIMOTO","Inclusion Criteria:\n\n* Patients with a Montreal Cognitive Assessment (MoCA) score, corrected for age and education, equal to or greater than 20.\n* Subjects capable of walking independently (Functional Ambulation Categories - FAC \\> 2).\n\nExclusion Criteria:\n\n* Cognitive impairments that compromise the understanding and\u002For execution of the proposed exercises.\n* Associated comorbidities that prevent maintaining an upright position or walking (e.g., hypotension).\n* Refusal or inability to provide informed consent.\n* Patients with contraindications to the use of the technological equipment required for the dynamic movement pathway.","60 Years",{"count":97,"type":21},[68],"\\*\\*Brief Summary\\*\\*\n\nThe study aims to explore how the integration of visual and motor systems can be trained and enhanced to improve gait rehabilitation in patients with various neurological and cardiovascular conditions. Scientific evidence highlights that physical activity requires coordination and precise processing of visual, auditory, and sensory information from the external environment, which is then integrated at the brain level. This process establishes synaptic connections that direct the movement of arms, hands, legs, and the trunk through bottom-up and top-down mechanisms. However, inaccurate or incomplete perceptual information can impair performance, even when accurate visual stimuli are provided, emphasizing the importance of assessing and enhancing visuo-motor integration.\n\nThe research investigates the central mechanisms controlling peripheral muscle activation patterns during gait. While over-ground walking in healthy individuals generally does not activate the prefrontal cortex except in dual-task scenarios, evidence suggests that post-stroke patients exhibit increased prefrontal cortex metabolism during walking. Recent studies have shown that gait training with exoskeletal systems improves walking patterns in post-stroke patients by altering muscle activation patterns and increasing fronto-parietal connectivity.\n\nThis study seeks to answer the following question: How do central and peripheral mechanisms interact to influence gait rehabilitation outcomes, and what role do visuo-motor integration and neuroplasticity play in this process? To address this, advanced neuroimaging technologies such as fMRI, dtMRI, and NIRS will be employed to investigate these mechanisms in vivo.",[276,277,30],"Neurological Diseases or Conditions","Cardiovascular Diseases",[279,280,281,282],"neurorehabilitation","gait rehabilitation","analysis of movement","neuroplasticity","2025-03-04",{"date":285,"type":46},"2025-03-05",{"date":287,"type":21},"2025-03",{"date":289,"type":21},"2027-02",{"name":291,"class":53},"IRCCS Centro Neurolesi Bonino Pulejo",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":86},"100582682","validation-and-scaling-of-screening-program-for-undiagnosed-myasthenia-gravis-social-media-campaign-paired-with-a-self-moderated-assessment-100582682","NCT06866483","Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment","Inclusion Criteria:\n\n* Reside within the 50 states of the United States at the time of enrollment\n* Age 19 or older if reside in Nebraska or Alabama, Age 21 or older if reside in Mississippi, Age 18 years or older if reside in any other state\n* Active email account\n* Fluency in English (spoken \u002F written), as demonstrated by the ability to read and sign the Informed Consent Form\n\nExclusion Criteria:\n\n* Live in an overseas territory of the United States\n* Inability or unwillingness to provide written informed consent\n* Diagnosed myasthenia gravis, including sero-negative MG\\*\n* Diagnosed multiple sclerosis\n* Have speech impairment, eye\u002Farm\u002Fleg weakness due to diagnosed brain cancer, or stroke",{"count":299,"type":21},1000,"This study expands and validates the pilot study NCT06381284. It is a fully remote, site-less, prospective, observational study enrolling adults in the United States (excluding U.S. territories) with undiagnosed neuromuscular symptoms. The primary objective is to determine the validity of a self-assessment tool in encouraging undiagnosed participants, recruited through a social media campaign, to seek medical evaluation for suspected myasthenia gravis (MG).",[302,30,303],"Myasthenia Gravis","Neuromuscular Manifestations",[305,306],"social media","myasthenia gravis",{"date":308,"type":46},"2025-03-10",{"date":310,"type":46},"2025-02-26",{"date":312,"type":21},"2025-12-31",{"name":314,"class":188},"ZS Associates",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":324,"conditions":325,"keywords":333,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":86},"100576905","the-prevalence-of-ryr1-related-disease-100576905","NCT06791369","The Prevalence of RYR1-related Disease","The Prevalence of RYR1-related Disease - an International, Collaborative Multicentre Study","Inclusion Criteria:\n\n* the presence of (an) unequivocally pathogenic RYR1 mutation(s)\n* clinical features of a recognized RYR1-related disorder (i.e. a congenital myopathy, MH or related phenotypes)\n* at least one specialist review at one of the national expertise centres\n* being resident in one of the participating countries.\n\nCriteria for the diagnosis of a congenital myopathy are the presence of suggestive clinical features and supportive muscle biopsy findings, or the presence of supportive histopathological findings in a first degree relative with similar clinical features and the same RYR1 genotype. Criteria for the diagnosis of MH susceptibility are clinical features suggestive of malignant hyperthermia (as defined by a diagnostic Larach score) and\u002For a positive IVCT\u002FCHCT test, or a relative with a history of MH and the same RYR1 genotype. Exclusion criteria will be a clinical diagnosis of a congenital myopathy or malignant hyperthermia without any of the supportive evidence as outlined above, or not being resident in one of the participating countries.\n\nExclusion Criteria:\n\n* a clinical diagnosis of a congenital myopathy or malignant hyperthermia without any of the supportive evidence as outlined above\n* not being resident in one of the participating countries.",{"count":323,"type":21},2000,"The skeletal muscle ryanodine receptor (RYR1) gene encodes an important calcium channel in skeletal muscle, with an important role in muscle contraction. Mutations (i.e. disease-causing changes) in RYR1 are associated with an immensely wide range of clinical problems, ranging from inborn muscle conditions with profound weakness at birth (\"congenital myopathies\"), to a potentially fatal anaesthesia complication (\"Malignant Hyperthermia, MH\") in otherwise healthy individuals. Although RYR1-related conditions are believed to be amongst the most common neuromuscular disorders, their precise prevalence (i.e. the number of cases in a particular population at a given time) is currently unknown. Moreover, there is no information regarding the relative frequency of specific congenital myopathies, MH and related manifestations, such as the associated bleeding abnormality recently described by our team.\n\nThe lack of reliable prevalence data represents a major obstacle to addressing the needs of individuals affected by RYR1-related conditions, to appropriate resource allocation, and to preparation for clinical studies (\"trial-readiness\") essential for therapy development.\n\nTo address this shortcoming, we will conduct an international collaborative study involving neuromuscular and MH centres from the UK and the Netherlands, focusing on the prevalence of RYR1-related conditions, as a group and per subtype. The countries participating in this study were included because of 1) centralized RYR1 testing, 2) the presence of at least one database\u002Fregistry with population-wide coverage capturing RYR1-related disorders and 3) of national myopathy and MH expertise centres. Information regarding RYR1-mutated individuals and their specific diagnosis will be obtained from national databases\u002Fregistries, and analysed utilizing statistical methods that are well-established in the field of epidemiology.\n\nThis study will provide important information regarding the actual disease burden of RYR1-related disorders on a wider scale, inform appropriate research resource allocation, and preparation for trial readiness. This study will be funded by the RYR1-Foundation.",[30,326,327,328,329,330,331,332],"Malignant Hyperthermia","Congenital Myopathy","Multiminicore Disease","Nemaline Myopathy","Centronuclear Myopathy","Central Core Disease","Congenital Fiber Type Disproportion",[334,335,326,327],"RYR1","Ryanodine Receptor Type 1","2025-01-22",{"date":338,"type":46},"2025-01-24",{"date":340,"type":21},"2025-02",{"date":342,"type":21},"2026-09",{"name":344,"class":53},"King's College London",{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":17,"minAge":353,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":240,"phases":4,"briefSummary":357,"conditions":358,"keywords":365,"overallStatus":120,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":201},"100569316","overview-use-of-respiratory-support-at-home-in-children-100569316","NCT06692660","Overview: Use of Respiratory Support At Home in Children","An Overview of the Use of Respiratory Support At Home in Children - Patients and Families Point of View","ELIPSE","Inclusion Criteria:\n\n* Children with respiratory support at home\n* Age 0 to 18 (not yet passed) years old\n\nExclusion Criteria:\n\n* Palliative care\n* Invasive ventilation\n* High flow oxygen therapy","0 Years","17 Years",{"count":356,"type":21},30,"the primary outcome is to describe the perceived success of the use of the respiratory support from the parent's point of view",[359,360,361,30,362,363,364],"Sleep Apnea Syndromes in Children","Obesity in Children","Bronchopulmonary Dysplasia (BPD)","Storage Disease","Malformation","Alveolar Hypoventilation",[366,367,368,369,370,371,372],"respiratory suport","sleep apnea syndrome","CPAP","BiPAP","ventilation","alveolar hypoventilation","non invasive ventilation","2024-11-14",{"date":375,"type":46},"2024-11-18",{"date":377,"type":21},"2024-11",{"date":379,"type":21},"2025-08",{"name":381,"class":53},"University Hospital, Grenoble"]